Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem cell transplantation

Stem Cells

Volumn 31, Issue 8, 2013, Pages 1715-1725

  Jitschin, Regina ^a   Mougiakakos, Dimitrios ^b,c   Von Bahr, Lena ^a   Völkl, Simon ^c   Moll, Guido ^a   Ringden, Olle ^a   Kiessling, Rolf ^b   Linder, Stig ^b   Le Blanc, Katarina ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Hematopoietic stem cell transplantation; Immune reconstitution; Immunotherapy; Mesenchymal stem cells

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; TRANSCRIPTION FACTOR FOXP3;

ADOPTIVE TRANSFER; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CELL DEATH; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; EPITHELIUM CELL; FEMALE; GRAFT VERSUS HOST REACTION; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE SYSTEM; MALE; MESENCHYMAL STROMA CELL; NATURAL KILLER CELL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH2 CELL;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNE RECONSTITUTION; IMMUNOTHERAPY; MESENCHYMAL STEM CELLS;

ADULT; AGED; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY, ADOPTIVE; MALE; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS;

EID: 84883375670     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1386     Document Type: Article

References (52)

1. Ferrara JL, Levine JE, Reddy P et al. Graft-versus-host disease. Lancet 2009;373:1550-1561.
2. Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol 2012;12:383-396.
3. von Bahr L, Sundberg B, Lonnies L et al. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant 2012;18:557-564.
4. Le Blanc K, Frassoni F, Ball L et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008;371:1579-1586.
5. Dander E, Lucchini G, Vinci P et al. Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring. Leukemia 2012; 26:1681-1684.
6. Chang YJ, Zhao XY, Huang XJ. Effects of the NK cell recovery on outcomes of unmanipulated haploidentical blood and marrow transplantation for patients with hematologic malignancies. Biol Blood Marrow Transplant 2008;14:323-334.
7. Reddy V, Iturraspe JA, Tzolas AC et al. Low dendritic cell count after allogeneic hematopoietic stem cell transplantation predicts relapse, death, and acute graft-versus-host disease. Blood 2004;103: 4330-4335.
8. Mougiakakos D, Jitschin R, von Bahr L et al. Immunosuppressive CD14(+)HLA-DR(low/neg) IDO(+) myeloid cells in patients following allogeneic hematopoietic stem cell transplantation. Leukemia 2012.
9. Luft T, Dietrich S, Falk C et al. Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood 2011;118:1685-1692.
10. Truitt RL, Atasoylu AA. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant 1991;8:51-58.
11. Young KJ, DuTemple B, Phillips MJ et al. Inhibition of graft-versushost disease by double-negative regulatory T cells. J Immunol 2003; 171:134-141.
12. Ezquer F, Ezquer M, Contador D et al. The antidiabetic effect of mesenchymal stem cells is unrelated to their transdifferentiation potential but to their capability to restore TH1/TH2 balance and to modify the pancreatic microenvironment. Stem Cells 2012;30:1664-1674.
13. Rieger K, Loddenkemper C, Maul J et al. Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. Blood 2006;107:1717-1723.
14. Mougiakakos D, Jitschin R, Johansson CC et al. The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood 2011;117: 4826-4835.
15. Fontenot JD, Rasmussen JP, Gavin MA et al. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005;6: 1142-1151.
16. Taylor PA, Panoskaltsis-Mortari A, Swedin JM et al. L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 2004;104:3804-3812.
17. Ratajczak P, Janin A, Peffault de Latour R et al. Th17/Treg ratio in human graft-versus-host disease. Blood 2010;116:1165-1171.
18. Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-2100.
19. Leveson-Gower DB, Olson JA, Sega EI et al. Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanism. Blood 2011;117:3220-3229.
20. Alpdogan O, Eng JM, Muriglan SJ et al. Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation. Blood 2005;105:865-873.
21. Vukicevic M, Chalandon Y, Helg C et al. CD56bright NK cells after hematopoietic stem cell transplantation are activated mature NK cells that expand in patients with low numbers of T cells. Eur J Immunol 2010;40:3246-3254.
22. Shimabukuro-Vornhagen A, Hallek MJ, Storb RF et al. The role of B cells in the pathogenesis of graft-versus-host disease. Blood 2009;114: 4919-4927.
23. Norlin AC, Sairafi D, Mattsson J et al. Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival. Bone Marrow Transplant 2008;41:267-273.
24. von Bahr L, Batsis I, Moll G et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells 2012;30: 1575-1578.
25. Seggewiss R, Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood 2010;115:3861-3868.
26. Lu X, Liu T, Gu L et al. Immunomodulatory effects of mesenchymal stem cells involved in favoring type 2 T cell subsets. Transpl Immunol 2009;22:55-61.
27. Pan L, Delmonte J, Jr, Jalonen CK et al. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995;86:4422-4429.
28. Li H, Guo ZK, Li XS et al. Functional and phenotypic alteration of intrasplenic lymphocytes affected by mesenchymal stem cells in a murine allosplenocyte transfusion model. Cell Transplant 2007;16:85-95.
29. Ramasamy R, Tong CK, Seow HF et al. The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function. Cell Immunol 2008; 251:131-136.
30. Krampera M. Mesenchymal stromal cell 'licensing': a multistep process. Leukemia 2011;25:1408-1414.
31. Devine SM, Cobbs C, Jennings M et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003;101:2999-3001.
32. Matsuoka K, Kim HT, McDonough S et al. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest 2010;120:1479-1493.
33. D'Asaro M, Dieli F, Caccamo N et al. Increase of CCR7-CD45RA+ CD8 T cells (T(EMRA)) in chronic graft-versus-host disease. Leukemia 2006;20:545-547.
34. Geginat J, Lanzavecchia A, Sallusto F. Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 2003;101:4260-4266.
35. Rasmusson I, Ringden O, Sundberg B et al. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res 2005;305:33-41.
36. Prasanna SJ, Gopalakrishnan D, Shankar SR et al. Pro-inflammatory cytokines, IFN-gamma and TNF-alpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS One 2010;5:e9016.
37. Magenau JM, Qin X, Tawara I et al. Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease. Biol Blood Marrow Transplant 2010;16:907-914.
38. Mielke S, Rezvani K, Savani BN et al. Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease. Blood 2007;110:1689-1697.
39. Koreth J, Matsuoka K, Kim HT et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011;365:2055-2066.
40. Andolfi G, Fousteri G, Rossetti M et al. Enforced IL-10 expression confers type 1 regulatory T cell (Tr1) phenotype and function to human CD4(+) T Cells. Mol Ther 2012;20:1778-1790.
41. Korn T, Bettelli E, Oukka M et al. IL-17 and Th17 cells. Annu Rev Immunol 2009;27:485-517.
42. Dander E, Balduzzi A, Zappa G et al. Interleukin-17-producing Thelper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation. Transplantation 2009;88:1261-1272.
43. Littman DR, Rudensky AY. Th17 and regulatory T cells in mediating and restraining inflammation. Cell 2010;140:845-858.
44. Yang XP, Ghoreschi K, Steward-Tharp SM et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol 2011;12:247-254.
45. Thoma MD, Huneke TJ, DeCook LJ et al. Peripheral blood lymphocyte and monocyte recovery and survival in acute leukemia postmyeloablative allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant 2012;18:600-607.
46. Arpinati M, Chirumbolo G, Urbini B et al. Acute graft-versus-host disease and steroid treatment impair CD11c+ and CD123+ dendritic cell reconstitution after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2004;10:106-115.
47. Cooper MA, Fehniger TA, Turner SC et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001;97:3146-3151.
48. Dulphy N, Haas P, Busson M et al. An unusual CD56(bright) CD16(low) NK cell subset dominates the early posttransplant period following HLA-matched hematopoietic stem cell transplantation. J Immunol 2008;181:2227-2237.
49. Ringden O, Remberger M, Persson U et al. Similar incidence of graftversus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995;15:619-625.
50. Ge W, Jiang J, Arp J et al. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation 2010;90: 1312-1320.
51. Bouffi C, Bony C, Courties G et al. IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One 2010;5:e14247.
52. Nemeth K, Keane-Myers A, Brown JM et al. Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc Natl Acad Sci U S A 2010;107: 5652-5657.